Eye To Eye: Zetia Concerns (CBS News)

All I know is that Zetia made me so sick I have been in the hospital. The side effects are horrible. They also hade be taking Lopid which many sites warn should not be done. I have stopped taking it and am beginning to feel better.
I'd rather die than take this stuff again!!!1

He's an ambulance chaser!!!!!!

Apart from the biggest study of all. The Heart Protection study... the most important study... oh wait and then there is CTT... hmmm when looking of patient groups in the 10's of thousands its amazing what results we get.

CTT was a meta-analysis. A study of studies where they can pick and choose what studies they include.

Statins do lower LDL. What statins DO NOT do is lower all-cause mortality. They don't make people healthier, nor live longer. The vast majority of your "10's of thousands" receive no benefit at all. A couple are saved a heart attack, a couple die cancer. NO NET BENEFIT to 99% of people.

There are no "amazing results"...there are miniscule results for very few people.

Are you focusing on High risk patients or just any ordinary patient. Because a HIGH RISK patient needs treatment, whilst a low risk does not. its simple. so are you talking about HIGH risk?

Dr. Marcia Angell, M.D., former editor-in-chief of the New England Journal of Medicine: "over the past two decades, the pharmaceutical industry has gained unprecedented control over the evaluation of its own products." She said that "drug companies now finance most clinical research on prescription drugs, and there is mounting evidence that they often skew the research they sponsor to make their drugs look better and safer."

The Treating to New Targets (TNT) Study: published in 2004, found that high doses of statins improved cardiovascular disease outcomes slightly but resulted in higher numbers of deaths from other causes.

ASCOT trial: fatal and nonfatal stroke was reduced by 27 %.9 The truth is that these events were seen in about 1.7 % of the statin-treated and in about 2.4 % in the non-treated patients, an absolute difference of 0.7 percentage points. But as this small difference of 0.7 is equivalent with 27 % of 2.4 percentage points, the misleading number 27 % was used, as is usual in the trial reports wanting to potentiate the apparent benefit of treatme

PROSPER trial:, total mortality was unchanged, because 22 fewer deaths from heart disease and stroke was outweighed by 24 more cancer deaths.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT): CONCLUSIONS: Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C.